Metagenomics and metabolomics to evaluate the potential role of gut microbiota and blood metabolites in patients with cerebral infarctionOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared gut microbiota and serum metabolites between 30 cerebral infarction patients and 30 healthy controls, all Han Chinese adults from North China. They looked for links between microbial composition, blood metabolites, and stroke pathology.
How was it studied?
Fecal DNA underwent 16S rRNA gene sequencing (V3-V4 region) on an Illumina MiSeq platform. Serum metabolites were profiled with UHPLC-MS/MS, then correlated with microbial taxa using Spearman analysis and a random forest model.
What did they find?
LEfSe analysis identified 72 taxa differing significantly between groups; 35 taxa, including Actinobacteriota and Peptostreptococcales-Tissierellales, were enriched in healthy controls. A random forest model narrowed this to 22 key taxa distinguishing patients from controls, with ROC areas of 0.728 and 0.7076. Thirty serum metabolites, notably TMAO, showed strong correlations with specific bacterial genera in patients.
Why it matters
The findings support a gut-brain axis link in cerebral infarction, with reduced microbial diversity and altered metabolites like TMAO potentially driving inflammation and disease progression. The authors propose these microbiome and metabolite signatures as candidate biomarkers for future diagnosis and therapy, though the single-center design limits generalizability.